{
    "id": 15649,
    "cites": 31,
    "cited_by": 12,
    "reference": [
        "Becker, G.S. and K.M. Murphy. (1993). A Simple Theory of Advertising as a Good. The Quarterly Journal of Economics, v108 (4); 941-964.",
        "Becker, G.S., T. Philipson and R.R. Soares. (2003). The Quantity and Quality of Life and the Evolution of World Inequality. American Economic Review, v95; 277291.",
        "Card, D.E., C. Dobkin and N. Maestas. (2004). The Impact of Nearly Universal Insurance Coverage on Health Care Utilization and Health: Evidence from Medicare Mar., NBER Working Paper No. W10365. Available at SSRN: http ://ssrn.comlabstract=5 16706 Cutler, D.M. (2004). Your Money or Your Life: Strong Medicine for America's Health Care System. Oxford University Press, New York, NY.",
        "Dow, W.H., T. Philipson, X. Sala-i-Martin. (1999). Longevity Complementarities under Competing Risks. The American Economic Review, v89 (5) Dec.; 1358-1371.",
        "Drummond, M.F., B. O'Brien, G.L. Stoddart, and G.W. Torrance. (1997). Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press.",
        "Finkelstein, A. and R. McKnight. (2005). What Did Medicare Do (and Was It Worth It)? Sept., NBER Working Paper No. Wl 1609 Available at SSRN: http ://ssrn. comlabstract=80425 5 Fischl, M. A., D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, 0. L. Laskin, J.",
        "Garber, A.M. and C.E. Phelps. (1997). Economic Foundations of Cost-Effectiveness Analysis, Journal of Health Economics, v16; 1-32.",
        "Garber, A.M. (1999). Advances in Cost-Effectiveness Analysis of Health Interventions, NBER WorkingPaperNo. 7198.",
        "Goldman, D., G. Joyce, G. Lawless, W. Crown, and V. Willey. (2007). Benefit Design and Specialty Drug Use, Health Affairs, v25 (5); 1319-1331.",
        "Hausman, J. (2000). Efficiency Effects On The U.S. Economy From Wireless Taxation, National Tax Journal, v53 (Part 2); 73 3-942.",
        "Himmelstein D., E. Warren, D. Thorne, and S. Woolhandler. (2005). Illness and Injury as Contributors to Bankruptcy, Health Affairs, Feb. 2. Web exclusive 10. 1377/hlthaff.w5.63. http://content.healthaffairs.org/cgi/content/full/hlthaff.w5. 63/DC 1 Hirth, R.A., M.E. Chernew, E. Miller, A.M. Fendrick, and W.G. Weissert. (2000). Willingness to Pay for a Quality Adjusted Life Year: In Search of a Standard. Medical decision Making, v20; 332-342.",
        "Hogan, C., J. Lunney, J. Gabel, and J. Lynn. (2001). Medicare Beneficiaries Cost of Care in the Last Year of Life, Health Affairs, v4 (20); 188-195.",
        "Johannesson, M., and M.C. Weinstein. (1993). On the Decision Rules of CostEffectiveness Analysis, Journal of Health Economics, v 12; 459-467.",
        "Lemp, G. F., S. F. Payne, D. Neal, T. Temelso and G. W. Rutherford (1990). Survival Trends for Patients with Aids. JAMA 263(3): 402-406.",
        "Lubitz, J.D. and G.F. Riley. (1993). Trends in Medicare Payments in the Last Year of Life. New England Journal of Medicine, v328 (15); 1092-1096.",
        "McLeod, G. X. and S. M. Hammer (1992). Zidovudine: Five Years Later. Ann Intern Med 117(6): 487-50 1.",
        "Moore, R. D., J. Hidalgo, B. W. Sugland and R. E. Chaisson (1991). Zidovudine and the Natural History of the Acquired Immunodeficiency Syndrome. N Engi J Med 324(20): 14121416.",
        "Murphy, M. and R. Topel. (2003). The Economic Value of Medical Research. in Measuring the Gains from Medical Research: An Economic Approach, (Murphy and Topel, eds). University Of Chicago Press; 41-73.",
        "Nadler, E., B. Eckert and P.J. Neumann. (2006). Do Oncologists Believe New Cancer Drugs Offer Good Value? The Oncologist, vll (2); 90-95.",
        "Phelps, C.E., and S.T. Parente. (1990). Priority Setting in Medical Technology and Medical Practice Assessment, Medical Care, v28; 703-723.",
        "Philipson, T. and G.S. Becker. (1996). Old-Age Longevity and Mortality-Contingent Claims. Journal of Political Economy, v 106; 551-573.",
        "Philipson, T. and A.B. Jena. (2006). Cost-Effectiveness Analysis and Innovation, Journal of Health Economics.",
        "Philipson, T. J. and A. B. Jena (2006). Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for Hiv/Aids Drugs. Forum for Health Economics & Policy 9(2).",
        "Philipson, T., S. Mechoulan, and A.B. Jena. (2006). Intellectual Property and External Consumption Effects: Generalizations from Health Care Markets., forthcoming, Journal of Law & Economics.",
        "Raisel, E., K. Weinfurt, and K. Schulman. (2005). Can Prospect Theory Explain RiskSeeking Behavior by Terminally Ill Patients, Medical Decision Making, v25; 609-613.",
        "Detels and A. Mufloz (2005). Patterns of the Hazard of Death after Aids through the Evolution of Antiretroviral Therapy: 1984-2004. AIDS 19(17): 2009-2018.",
        "The Antiretroviral Therapy Cohort Collaboration (2008). Life Expectancy of Individuals on Combination Antiretroviral Therapy in High-Income Countries: A Collaborative Analysis of 14 Cohort Studies. The Lancet 372(9635): 293-299.",
        "Vella, S., M. Giuliano, P. Pezzotti, M. G. Agresti, C. Tomino, M. Floridia, D. Greco, M. Moroni, G. Visco, F. Milazzo, F. Giannelli, G. Angarano, L. Ortona, C. Zanussi, Italian Zidovudine Evaluation Group, M. Barbanera, A. Cajozzo, G. F. Calonghi, R. Caputo, P.",
        "Weinstein, M.C., and W.G. Manning. (1997). Theoretical Issues in CostEffectiveness Analysis Journal of Health Economics, v 16; 121-128.",
        "Walensky, Rochelle P., A. D. Paltiel, E. Losina, Lauren M. Mercincavage, Bruce R. Schackman, Paul E. Sax, Milton C. Weinstein and Kenneth A. Freedberg (2006). The Survival Benefits of Aids Treatment in the United States. The Journal of Infectious Diseases 194(1): 11-19.",
        "Weinstein, M.C., and W.B. Stason. (1977). Foundations of Cost-Effectiveness Analysis for Health and Medical Practices. New England Journal of Medicine, v296; 716721."
    ]
}